3555 Arden Road
18 articles about Predicine
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC
Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib plus Cetuximab study in Nature Medicine.
Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib
Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine, demonstrating the clinical utility of its minimal residual disease Liquid Biopsy Assay in support of Genentech's Phase 1 Clinical Trial of Divarasib.
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
Predicine announced that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease liquid biopsy assay to genitourinary cancers at the 2023 American Urological Association Annual Meeting held in Chicago between April 28 to May 1, 2023.
Predicine, a global molecular insights company, announced that it will present data from 12 studies and introduce PredicineALERT™, a next-generation Minimal Residual Disease liquid biopsy assay at the 2023 AACR Conference on April 14-19, 2023.
Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays
Predicine, a global molecular insights company, is committed to advancing genitourinary cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing assays.
Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive next-generation liquid biopsy solution that provides genome-wide, genomic and epigenomic insights to capture the mutational landscape and the immune signature of cancer and to help support cancer research and clinical drug development.
Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration
Predicine, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the PredicineCARETM cfDNA Assay, a Next-Generation Sequencing (NGS) assay for tumor mutation profiling in cfDNA isolated from liquid biopsy samples from cancer patients.
Predicine to Present New Data at ESMO 2022 Demonstrating the Utility of its Portfolio of Liquid Biopsy Tests for Cancer Patients
Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held September 9-13, 2022, in Paris, France.
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine.
Predicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection Kit
Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today a nationwide expansion of its COVID-19 testing solution through the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of Predicine’s SARS-CoV-2 RT-PCR test and self-collection kit.
Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners
Epic’s Comprehensive Cancer Profiling™ now includes the broadest ctDNA assay PredicineATLAS™
Predicine and Merck KGaA, Darmstadt, Germany to Present Data at AACR – Advances in Liquid Biopsy Conference 2020
Predicine and Merck KGaA, Darmstadt, Germany collaboratively highlight the importance of multi-parametric profiling of ctDNA and cfRNA for holistic molecular insight for detecting driver mutation, monitoring disease burden and drug resistance in advanced stage colorectal cancer.
Predicine and Kintor Pharmaceuticals Collaborate on Precision Oncology Clinical Trials and Companion Diagnostics Development
Predicine, a precision medicine company based in Silicon Valley, announced today that the company has entered into a global strategic partnership with Suzhou Kintor Pharmaceuticals to increase the speed and efficiency of biomarker-driven global clinical trials for Kintor’s novel oncology drugs and the development of companion diagnostics for FDA and CFDA approvals.
Predicine Launches PredicineATLAS, a 600-gene Blood-based TMB Panel to Accelerate Immuno-oncology Clinical Trials
The panel is expected to be one of the industry's largest liquid biopsy panels, covering gene content of major commercially available TMB panels in the immunotherapy space.